Genenta Science S.p.A. engages in the development of hematopoietic stem cell gene therapies.The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
